Results 51 to 60 of about 10,512 (252)
Aggressive and Malignant Prolactinomas [PDF]
Neuroendocrinology, 2019 Prolactin-secreting tumors (prolactinomas) represent the most common pituitary tumor type, accounting for 47–66% of functional pituitary tumors. Prolactinomas are usually benign and controllable tumors as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and ...
Eyrc +8 more
openaire +8 more sources
Clinical characteristics and presence of prolactinoma in women with hyperprolactinemia
Iatreia, 2016 Objectives: To clinically characterize women with hyperprolactinemia at InSer Pereira (Colombia) and to determine the prevalence of prolactinoma. Methods: Retrospective description of 45 patients with hyperprolactinemia, and contrasted pituitary magnetic
López-Clavijo, Carlos Alberto +3 more
doaj +1 more source
BMC Endocrine Disorders, 2021 Background Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal.
Yunzhi Zou +6 more
doaj +1 more source
Clinical Endocrinology, EarlyView.ABSTRACT Objective Detecting hypotonic urine (specific gravity < 1005 g/L) is crucial for the early identification of arginine vasopressin deficiency (AVP‐deficiency), a common complication after pituitary surgery. This study aimed to evaluate the agreement between urine specific gravity measurements taken by patients using urine test strips and those ...
Jeanne‐Marie Nollen +7 more
wiley +1 more source
Paediatric and Perinatal Epidemiology, EarlyView.Abstract Background Cancer is the leading cause of death in children aged 1–14 and the second in 15‐19‐year‐old adolescents in Spain. The Paediatric Population‐Based Cancer Registry of the Community of Madrid was created to monitor its incidence and survival.
Raquel López‐González +5 more
wiley +1 more source
Management of prolactinoma during pregnancy and postpartum
Journal of Integrated Health Sciences, 2015 Prolactinoma is classified as microprolactinoma when it measures
Om J Lakhani +3 more
doaj +1 more source
AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. [PDF]
, 2019 Background: Pituitary adenomas have a high disease burden due to tumor growth/ invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be ...
Cano González, David A. +2 more
core
Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. [PDF]
, 2013 OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly
AMATO, Marco Calogero +4 more
core +1 more source
Clinical Case Reports, Volume 13, Issue 4, April 2025.ABSTRACT Due to its rare incidence, pituitary adenoma requires high vigilance and suspicion. Therefore, physicians should consider this differential diagnosis and perform the necessary workup, such as an overnight or standard dexamethasone suppression test and brain magnetic resonance imaging (MRI), to rule it out if sudden hormonal changes without any
Shadi Niliyeh +4 more
wiley +1 more source
Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion
Open Chemistry, 2018 Prolactinoma is the most frequently diagnosed pituitary tumors. Dopamine agonists (DAs) are recognized as first-line therapy; however, approximately 10% patients will develop resistance to DAs therapy.
Liu Qian +5 more
doaj +1 more source